Patients Diagnosed With Metastatic Castration-sensitive Prostate Cancer and High Serum Lactate Dehydrogenase Levels Did Not Receive an Adequate Dose of Cabazitaxel

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational analysis identified high LDH levels as major barriers to receiving cabazitaxel in mCRPC, suggesting urgent assessment is needed.

Patients with high lactate dehydrogenase levels were unable to receive adequate cabazitaxel treatment.
An odds ratio of 6.22 indicated a significant link between LDH levels and not receiving sufficient cabazitaxel cycles.
The median overall survival for patients with LDH ≥326 U/l was only 22 months compared to 72 months for those with lower levels.
Evaluating LDH levels at diagnosis could lead to better management strategies for mCRPC patients.

Nakai et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis identified high LDH levels as major barriers to receiving cabazitaxel in mCRPC, suggesting urgent assessment is needed.